Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 296
- Registration Number
- NCT06620822
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT06618664
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
Surgery for Ovarian Cancer After PARPi Therapy in Precision
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Gynecologic Oncology Group
- Target Recruit Count
- 33
- Registration Number
- NCT06602063
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China
🇨🇳Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Bortezomib Combined With PD-1 mAb and mFOLFIRINOX for Metastatic Pancreatic Cancer
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 63
- Registration Number
- NCT06572813
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 39
- Registration Number
- NCT06564298
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT06558227
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 40
- Registration Number
- NCT06555471
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 68
- Registration Number
- NCT06543836
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Jinzhou Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT06512207
- Locations
- 🇨🇳
The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 30
- Registration Number
- NCT06512467
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath